Advancement of two late-stage pipeline therapies raises new prospects for dry eye syndrome

15 May 2020 (Last Updated May 15th, 2020 16:00)

The dry eye syndrome treatment paradigm is looking brighter as two late-stage pipeline therapies have recently posted major updates - the first regarding corticosteroid therapy and the second related to therapy with an innovative route of administration for the condition.

If approved, these therapies could heighten enthusiasm among physicians and patients within this designation, though the extent of this enthusiasm could be subtle upon further inspection of the wider impact of these therapies on the treatment paradigm. Read more here.